Oncologica is a world leading precision cancer medicine and Covid-19 testing and genomic sequencing laboratory based in Cambridge, UK. Our personalised cancer DNA profiling is used to precisely identify the most appropriate clinical targeted therapies and/or immunotherapies which can be used to treat patients as an alternative to chemotherapy.  

Our molecular Next Generation Sequencing capabilities are used to sequence tumour DNA and Covid-19/ SARS-CoV-2 for virus mutations. SARS-CoV-2 testing, and sequencing is used to identify high risk Covid-19 variants which can potentially bypass the vaccine. Oncologica’s NGS DNA profiling covers 505 genes with linkage to over 750 targeted therapies to provide patients and clinicians with detailed genomic blueprints that optimize therapy choices and improve outcomes. 

Oncologica also undertakes Contract Research supporting biomarker development programmes, clinical trials, and the validation of new diagnostic testing platforms. Our in-house R&D activities focus on the development of novel cancer genomic based diagnostic and therapeutic approaches. 

Our government approved Oncofocus and Coronofocus lab tests are used by healthcare providers the private sector, businesses, transport, and educational institutions. Personalised genomic data helps empower patients and clinicians to increase treatment efficacy and improve human health.

Oncologica UK

Org chart

Teams

Offices